Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You didn’t read the commentary. If the Tech proves itself and is approved the the FDA then yes the company will find itself in a much better position and analysts will cover it. That is nowhere near reality today, but with a couple approvals and real sales, then we have a whole new ballgame.
Regardless of timing, leadership has failed to build credibility for years. Great technology, poor execution.
Actions speak louder than words. Elite does not yet have a trustworthy leadership, pipeline of products and they trade on the OTC. The company is barely scraping by. They are not on the verge of bankruptcy, but as of now they shouldn’t be given any sort of forward multiple of any kind.
The company needs to start building credibility with both approvals, reduce CRLs, and hitting timelines they set.
No credible buy side investment firm will touch this stock. Smaller family owned firms might as they are smaller and may be willing to take on more risk.
With MiFid II going to destroy the sell-side analyst structure, there won’t be any credible analyst coverage until the company proves itself and can get off the OTC with real real products and real revenue.
Until the company can start acting on years of promises the stock price will go nowhere. We may be nearing upcoming approvals of Perc & Norco in 1H 2017. We’ll know soon enough.
They still need to file their 1st Sungen product. Several weeks late already. CEO is starting to execute, by the timeline he sets is NEVER hit.
Just an FYI that “alternative facts” aren’t real.
I still completely agree that the CFO is a dud and the CEO would be ridiculous to pursue going alone. I will stand by those comments all day long.
Your comments still doesn’t prove this is a P&D scheme, denounce the tech or the potential upcoming approvals.
I’d love to hear of proof otherwise.
Yes, but only from the standpoint of switching exchanges in the next couple of years.
Nice volume last 10 minutes. Continue to see some big trades
Only news after the bell on Fridays is news you do not want to hear.
What in the world?! The exchanges do not double count the same shares twice. A lot of 100 shares sold/bought is just that - 100, no more or less.
You do realize you posted during market open, right?
Missed it, but could just be different MM’s balancing out from yesterday pre-market. How much was 2nd?
*session
My guess is that it is a true up from yesterday’s season.
Went up too far too fast on zero news. I am expecting it will pull back with some strength in early session.
Was probably the same person as Couch and several others.
Pure garbage. This has not been updated since they stopped trading on the AMEX. Another fake news poster.
Have you seen him get paid for crappy Mikah deals? How much CASH did he get for Trimipramine?
Of course it hasn’t been mentioned since. The company doesn’t have the financial strength to justify its market cap. Stock isn’t going anywhere if all they have is to promote Phendimetrazine and Trimipramine, but Nasrat’s pockets seemed to be filling just fine.
That is about as accurate as Nasrat saying the FDA can’t stop us. Management has stated that a RS is a potential option. They have never rescinded this comment, so it remains as such. Anything said otherwise did fake news.
I actually think it was a mixture of both arguments. We don’t know how many years Nasrat has been holding back from communicating the Tmax data that would have given him foresight into the company’s position a few year’s out since they put all their eggs in one basket, SequestOx. Knowing this they would have little to no cash and gave him a way to get an annual interest payment to boot.
Now throw in all the self-dealing non-arms length transactions with Mikah. Brilliant if you ask me. Greedy, but brilliant.
Or down 89% from the high. It is all relative.
Nasdaq - Here we are where? With terrible market cap, bloated OS and multiple CRL’s?
*agree
Hahaha! Totally free with your comment, totally.
Current sales are worthless for the bloated share count and lack of tangible execution from management over the past several years.
Management put all their eggs in one basket and that failed to materialize. Their strategy of revenue diversification comes several years too late.
No doubt about it - 2018 will make or break Elite.
That could be why they received NAI status as they are still up to all codes, standards & regulations. It was a separate filing and would still need to undergo same review & inspection.
It was specifically for a “filed generic” product. That could have meant Phendimetrazine Tartrate, which is what we saw approved 2 weeks later.
Question for the group - was the pre-approval inspection communicated in the Dec 8-K related to Phendimetrazine Tartrate, the récent approval (cause 2 is better than 1?) or some different drug?
I think Perc may bring in a little $, but not huge. Oxy would be a bigger winner, but slower to actually get to the point of real revenue.
I couldn’t edit when I post on my phone. Yes, Purdue will sue with Oxy, not Perc.
FDA approval would be great for Perc, but may mean nothing for sales. Purdue will sue and trigger the 30-month stay pushing Perc revs put another few years + force Elite to incur expensive legal expenses.
Because the "n" completely throws off the intent of the comment. Really grasping at straws here.
Like Diane actually works past noon. Lol
Patents are great and all, but I haven’t heard about any Canadian applications.
I could be misremembering, but wasn’t the Norco CRL communicated in the Q?
Thanks for revisiting the script. I am traveling and won’t have time for a couple more days. Appreciate the clarification.
America could use a few more fat pills. Lol
During the last cc they mentioned they had 30 days to respond to FDA on Perc and Norco. I assume Sungen product got delayed. I am ASSUMING they responded in time. Nasrat clearly mentioned that if they didn’t respond timely they would have to get in the back of the line...
I believe Perc was for the minor amendment that should be remedied quickly. Knowing they replied to the FDA by mid-December, I would hope to hear an FDA response by early Feb - about a week before the quarterly conference call.